← 返回

基于多组学数据库整合分析鉴定 KIFC3 作为结直肠癌生物标志物及其在免疫微环境中的调控机制

英文原题:Identification of KIFC3 as a Colorectal Cancer Biomarker and Its Regulatory Mechanism in the Immune Microenvironment Based on Integrated Analysis of Multi-Omics Databases.

查看英文原题

Identification of KIFC3 as a Colorectal Cancer Biomarker and Its Regulatory Mechanism in the Immune Microenvironment Based on Integrated Analysis of Multi-Omics Databases.

PubMed 2025/04/02(内容时间) Biomedicines Q2 · IF 4.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

研究表明驱动蛋白家族(KIF)成员可促进结直肠癌(CRC)的发生。然而,其作用机制尚未阐明。本研究旨在通过分析多组学数据,识别与KIF成员相关的CRC生物标志物,并探讨其在结直肠癌治疗中的生物学机制。

使用CRC相关数据集和KIF成员相关基因(KIFRGs)。首先,分别使用不同的表达分析(CRC vs. 对照)在TCGA-CRC中识别差异表达基因(DEGs)和差异表达甲基化基因(DEMGs)。通过重叠DEGs、DEMGs和KIFRGs筛选交集基因。使用生存分析(p < 0.05)识别候选基因。随后,基于候选基因,通过基因表达验证和生存分析筛选生物标志物。随后,进行功能富集、免疫细胞浸润和药物敏感性分析。利用单细胞分析进行细胞注释,然后进行功能富集和伪时序分析。

通过重叠12,479个DEGs、11,319个DEMGs和43个KIFRGs,识别出12个交集基因。生存分析显示,驱动蛋白家族成员C2(KIFC2)和驱动蛋白家族成员C3(KIFC3)在生存方面存在显著差异(p < 0.05)。此外,KIFC3通过了基因表达验证和生存分析验证(p < 0.05);因此,KIFC3被视为生物标志物。随后,检测了KIFC3涉及的通路,如Ecm受体交互和趋化因子信号通路。此外,我们发现KIFC3与自然杀伤(NK)细胞(r = 0.455,p < 0.05)和NK T细胞(r = 0.411,p < 0.05)显著正相关。而且,在CRC的药物敏感性中,检测到AZD.2281、nilotinib、PD.173074和shikonin的潜在治疗益处。此外,使用单细胞分析,注释了16个细胞簇,上皮细胞和M2样巨噬细胞富集于“类风湿关节炎”。另外,我们观察到大多数M1样巨噬细胞存在于分化早期,而M2样巨噬细胞在分化后期占主导地位。

本研究通过多组学分析将KIFC3确定为CRC生物标志物,突出了其独特的表达、生存关联、免疫相关性和药物敏感性,具有潜在的诊断和治疗应用价值。

展开英文摘要原文

Background: Studies suggest that kinesin family (KIF) members can promote the occurrence of colorectal cancer (CRC).

However, the mechanism of action has not yet been elucidated. The aim of this study was to identify CRC biomarkers associated with KIF members and to investigate their biological mechanisms in the treatment of colorectal cancer by analyzing multi-omics data. Methods: CRC-related datasets and KIF member-related genes (KIFRGs) were used. First, differentially expressed genes (DEGs) and differentially expressed methylation genes (DEMGs) in the TCGA-CRC were identified separately using different expression analyses (CRC vs. control). The intersecting genes were selected by overlapping the DEGs, DEMGs, and KIFRGs. Candidate genes were identified using survival analysis ( p < 0.

05). Subsequently, based on the candidate genes, biomarkers were selected by gene expression validation and survival analysis. Subsequently, functional enrichment, immune cell infiltration, and drug sensitivity analyses were performed. Single-cell analysis was utilized to perform cell annotation, and then function enrichment and pseudo-temporal analyses were performed.

Results: The 12 intersecting genes were identified by overlapping 12,479 DEGs, 11,319 DEMGs, and 43 KIFRGs. The survival analysis showed that Kinesin Family Member C2 (KIFC2) and Kinesin Family Member C3 (KIFC3) had significant differences in survival ( p < 0. 05).

Moreover, KIFC3 passed the gene expression validation and survival analysis validation ( p < 0. 05); thus, KIFC3 was deemed a biomarker. Subsequently, the pathways involved in KIFC3 were detected, such as the Ecm receptor intersection and chemokine signaling pathway.

In addition, we found that KIFC3 was significantly positively correlated with natural killer (NK) cells (r = 0. 455, p < 0. 05) and NK T cells (r = 0. 411, p < 0. 05).

Moreover, in the drug sensitivity of the CRC, the potential therapeutic benefits of AZD. 2281, nilotinib, PD. 173074, and shikonin were detected.

Furthermore, using single-cell analysis, 16 cell clusters were annotated, and epithelial cells and M2-like macrophages were enriched in "rheumatoid arthritis".

Additionally, we observed that most M1-like macrophages were present in the early stages of differentiation, whereas M2-like macrophages were predominant in the later stages of differentiation. Conclusions: This study identifies KIFC3 as a CRC biomarker through multi-omics analysis, highlighting its unique expression, survival association, immune correlations, and drug sensitivity for potential diagnostic and therapeutic applications.

论文信息

作者
Wang F、Zeng X、Wen J、Xian K、Jin F、Jiang S、Sun L
第一作者单位
Department of Medical, Peking University Shenzhen Hospital, Shenzhen 518000, China.China
通讯作者单位
Department of Health Management Centre, Zhongshan Hospital, Fudan University, Shanghai 200032, China.China
期刊
Biomedicines2025 Apr 2
原文标识
PubMed 40299423 · DOI 10.3390/biomedicines13040859